Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Mallinckrodt
US Department of Justice
Deloitte
McKinsey
Julphar
Cipla
Covington
US Army

Generated: October 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020381

« Back to Dashboard

NDA 020381 describes NIASPAN TITRATION STARTER PACK, which is a drug marketed by Abbvie and is included in one NDA. It is available from six suppliers. Additional details are available on the NIASPAN TITRATION STARTER PACK profile page.

The generic ingredient in NIASPAN TITRATION STARTER PACK is niacin. There are fourteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the niacin profile page.
Summary for 020381
Tradename:NIASPAN TITRATION STARTER PACK
Applicant:Abbvie
Ingredient:niacin
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 020381
Ingredient-typeNicotinic Acids
Medical Subject Heading (MeSH) Categories for 020381
Suppliers and Packaging for NDA: 020381
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381 NDA AbbVie Inc. 0074-3074 0074-3074-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3074-30)
NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381 NDA AbbVie Inc. 0074-3074 0074-3074-90 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3074-90)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength375MG
Approval Date:Jul 28, 1997TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength500MG
Approval Date:Jul 28, 1997TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Mar 15, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
Patent:➤ Sign UpPatent Expiration:Mar 15, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN

Expired US Patents for NDA 020381

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Sign Up ➤ Sign Up
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Sign Up ➤ Sign Up
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 ➤ Sign Up ➤ Sign Up
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 ➤ Sign Up ➤ Sign Up
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-004 Jul 28, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chinese Patent Office
AstraZeneca
Merck
Federal Trade Commission
Cantor Fitzgerald
Baxter
Healthtrust
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.